title: HIV vaccine development and evaluation: realistic expectations.
abstract: As of January 1998, more than 85 vaccines for 24 clinical indications are currently licensed in the United States. From the time of discovery of the etiologic agent to the development of a licensed vaccine, many years have usually been required. Although many vaccines have been licensed on the basis of one efficacy trial, multiple vaccine concepts and multiple efficacy trials (both in the United States and internationally) have at times been necessary. Over a relatively short period of time, there has been remarkable progress in human immunodeficiency virus (HIV) vaccine development, with over 34 different HIV candidate vaccines having been tested in phase 1 trials, and three having been tested in phase 2 trials. In spite of our incomplete understanding of HIV pathogenesis and correlates of protection, the first phase 3 efficacy trial has been initiated in the U.S. and tentative plans have been announced for three other phase 3 efficacy trials with the most advanced HIV candidate vaccines to begin in the next 3 years. Like many previous vaccine development efforts, these initial HIV vaccine efficacy trials could be the first of many large-scale efficacy trials in the future, testing various vaccine design concepts among different high-risk populations in both developed and developing countries. The choice of when and how to proceed to phase 3 trials remains a complex decision, but it is likely that only through such trials will further knowledge be gained to advance this important effort and reach our goal of a safe and effective HIV vaccine.
authors.affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
authors.forename: W L
authors.initials: WL
authors.lastname: Heyward
authors.forename: K M
authors.initials: KM
authors.lastname: MacQueen
authors.forename: K L
authors.initials: KL
authors.lastname: Goldenthal
mesh_terms: D016915:AIDS Vaccines; D001428:Bacterial Vaccines; D015195:Drug Design; D004341:Drug Evaluation; D006193:Haemophilus influenzae / Q000276:immunology; D016174:Hepacivirus / Q000276:immunology; D017325:Hepatitis B Vaccines; D006801:Humans; D008954:Models, Biological; D012401:Rotavirus / Q000276:immunology; D014765:Viral Vaccines
chemical_list: D016915:AIDS Vaccines; D001428:Bacterial Vaccines; D017325:Hepatitis B Vaccines; D014765:Viral Vaccines